FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

Ever wondered how JavaScript really works? In this video, we break down the computer science behind the world’s most popular programming language - from source code to execution? Learn how the engine ...

Ever wondered how JavaScript was created and how it became the world’s most popular programming language?From its early days in Netscape to powering modern web apps, servers, and beyond, this video ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

The last time I wrote about Replimune Group, Inc. (REPL) it was in a Seeking Alpha article entitled "Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch." With respect to this ...